Login to Your Account



Survey: Price Key In ED Race As Firms Vie To Steal Viagra Market

By Randall Osborne


Monday, May 12, 2003

What a difference a year makes. Or not.

At this point in 2002, ICOS Corp. had just received word from the FDA that its erectile dysfunction drug candidate Cialis (taladifil), partnered with Eli Lilly and Co., was approvable if three issues were cleared up. (See BioWorld Financial Watch, May 6, 2002.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription